金纳米粒子:神经退行性疾病的诊断和治疗应用
Xin Hu1, Jingxian Cheng1, Ruri Yuan2
1Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education; Luzhou Municipal Key Laboratory of Thrombosis and Vascular Biology; Laboratory for Cardiovascular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, China.
Journal of drug targeting
|May 21, 2025
概括
黄金纳米粒子 (GNPs) 通过改善跨血脑屏障的药物输送来诊断和治疗神经退行性疾病 (NDDs) 是有前途的. 毒性和成本效益等挑战需要进一步研究临床转化.
科学领域:
- 纳米医学是一种纳米医学.
- 神经科学是一个神经科学.
- 生物技术是生物技术.
背景情况:
- 像阿尔茨海默氏症和帕金森症这样的神经退行性疾病 (NDD) 构成了日益增长的全球健康负担.
- 目前的治疗方法面临局限性,特别是在跨越血脑屏障 (BBB) 的药物输送方面.
研究的目的:
- 在诊断和治疗NDD中全面审查金纳米颗粒 (GNP) 的应用.
- 识别和解决阻碍GNP对NDD临床转化所面临的挑战.
主要方法:
- 对NDDs的GNP现有文献的系统审查.
- 分析当前的临床研究和研究轨迹.
- 对药物动力学,代谢,毒性和生物相容性数据的评估.
主要成果:
- 在NDDs方面,GNP显示出在整个BBB中增强药物输送的巨大潜力.
- 主要挑战包括药理动力学,毒性,长期生物相容性,监管障碍和成本效益.
结论:
- GNPs为推进NDD诊断和治疗提供了一个有前途的平台.
- 解决已确定的挑战对于实现NDD管理中GNP的全部临床潜力至关重要.
相关概念视频
01:22Alzheimer's Disease: Treatment
139
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
139
01:26Alzheimer's Disease: Overview
405
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
405